Missense and truncating variants in CHD5 in a dominant neurodevelopmental disorder with intellectual disability, behavioral disturbances, and epilepsy.


Journal

Human genetics
ISSN: 1432-1203
Titre abrégé: Hum Genet
Pays: Germany
ID NLM: 7613873

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 29 01 2021
accepted: 15 04 2021
pubmed: 5 5 2021
medline: 22 6 2021
entrez: 4 5 2021
Statut: ppublish

Résumé

Located in the critical 1p36 microdeletion region, the chromodomain helicase DNA-binding protein 5 (CHD5) gene encodes a subunit of the nucleosome remodeling and deacetylation (NuRD) complex required for neuronal development. Pathogenic variants in six of nine chromodomain (CHD) genes cause autosomal dominant neurodevelopmental disorders, while CHD5-related disorders are still unknown. Thanks to GeneMatcher and international collaborations, we assembled a cohort of 16 unrelated individuals harboring heterozygous CHD5 variants, all identified by exome sequencing. Twelve patients had de novo CHD5 variants, including ten missense and two splice site variants. Three familial cases had nonsense or missense variants segregating with speech delay, learning disabilities, and/or craniosynostosis. One patient carried a frameshift variant of unknown inheritance due to unavailability of the father. The most common clinical features included language deficits (81%), behavioral symptoms (69%), intellectual disability (64%), epilepsy (62%), and motor delay (56%). Epilepsy types were variable, with West syndrome observed in three patients, generalized tonic-clonic seizures in two, and other subtypes observed in one individual each. Our findings suggest that, in line with other CHD-related disorders, heterozygous CHD5 variants are associated with a variable neurodevelopmental syndrome that includes intellectual disability with speech delay, epilepsy, and behavioral problems as main features.

Identifiants

pubmed: 33944996
doi: 10.1007/s00439-021-02283-2
pii: 10.1007/s00439-021-02283-2
pmc: PMC8197709
doi:

Substances chimiques

Nerve Tissue Proteins 0
DNA Helicases EC 3.6.4.-
CHD5 protein, human EC 3.6.4.12

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1109-1120

Subventions

Organisme : Japan Agency for Medical Research and Development (AMED)
ID : JP20ek0109348
Organisme : Japan Agency for Medical Research and Development (AMED)
ID : JP20dm0107090
Organisme : Japan Agency for Medical Research and Development (AMED)
ID : JP20ek0109486
Organisme : Intramural research grants for Neurological and Psychiatric Disorders of NCNP from the Ministry of Health, Labour and Welfare
ID : 30-6 and 30-7
Organisme : Japan Agency for Medical Research and Development (AMED)
ID : JP20ek0109301
Organisme : JSPS KAKENHI
ID : JP17H01539
Organisme : JSPS KAKENHI
ID : JP20K08164
Organisme : NHGRI NIH HHS
ID : U01 HG007672
Pays : United States
Organisme : Japan Agency for Medical Research and Development (AMED)
ID : JP20kk0205012
Organisme : NIH Common Fund, through the Office of Strategic Coordination/Office of the NIH Director
ID : U01HG007672

Références

Adzhubei IA, Schmidt S, Peshkin L et al (2010) A method and server for predicting damaging missense mutations. Nat Methods 7:248–249. https://doi.org/10.1038/nmeth0410-248
doi: 10.1038/nmeth0410-248 pubmed: 20354512 pmcid: 2855889
Bagchi A, Papazoglu C, Wu Y et al (2007) CHD5 is a tumor suppressor at human 1p36. Cell 128:459–475. https://doi.org/10.1016/j.cell.2006.11.052
doi: 10.1016/j.cell.2006.11.052 pubmed: 17289567
Bishop B, Ho KK, Tyler K et al (2015) The chromatin remodeler chd5 is necessary for proper head development during embryogenesis of Danio rerio. Biochimica et Biophysica Acta (BBA) Gene Regul Mech 189:1040–1050. https://doi.org/10.1016/j.bbagrm.2015.06.006
doi: 10.1016/j.bbagrm.2015.06.006
Carlston CM, O’Donnell-Luria AH, Underhill HR et al (2017) Pathogenic ASXL1 somatic variants in reference databases complicate germline variant interpretation for Bohring-Opitz Syndrome. Hum Mutat. https://doi.org/10.1002/humu.23203
doi: 10.1002/humu.23203 pubmed: 28229513 pmcid: 5487276
Chen J, Zhang J, Liu A et al (2020) CHD2-related epilepsy: novel mutations and new phenotypes. Dev Med Child Neurol 62:647–653. https://doi.org/10.1111/dmcn.14367
doi: 10.1111/dmcn.14367 pubmed: 31677157
Collins RL, Glessner JT, Porcu E et al (2021) A cross-disorder dosage sensitivity map of the human genome. BMJ. https://doi.org/10.1101/2021.01.26.21250098
doi: 10.1101/2021.01.26.21250098
Delmas V, Stokes DG, Perry RP (1993) A mammalian DNA-binding protein that contains a chromodomain and an SNF2/SWI2-like helicase domain. Proc Natl Acad Sci 90:2414–2418. https://doi.org/10.1073/pnas.90.6.2414
doi: 10.1073/pnas.90.6.2414 pubmed: 8460153
Drivas TG, Li D, Nair D et al (2020) A second cohort of CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau syndrome. Eur J Hum Genet 28:1422–1431. https://doi.org/10.1038/s41431-020-0654-4
doi: 10.1038/s41431-020-0654-4 pubmed: 32483341 pmcid: 7608102
den Dunnen JT, Dalgleish R, Maglott DR et al (2016) HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat 37(6):564–569. https://doi.org/10.1002/humu.22981
doi: 10.1002/humu.22981
Egan CM, Nyman U, Skotte J et al (2013) CHD5 is required for neurogenesis and has a dual role in facilitating gene expression and polycomb gene repression. Dev Cell 26:223–236. https://doi.org/10.1016/j.devcel.2013.07.008
doi: 10.1016/j.devcel.2013.07.008 pubmed: 23948251
Fregeau B, Kim BJ, Hernández-García A et al (2016) De novo mutations of RERE cause a genetic syndrome with features that overlap those associated with proximal 1p36 deletions. Am J Hum Genet 98:963–970. https://doi.org/10.1016/j.ajhg.2016.03.002
doi: 10.1016/j.ajhg.2016.03.002 pubmed: 27087320 pmcid: 4863473
Havrilla JM, Pedersen BS, Layer RM, Quinlan AR (2019) A map of constrained coding regions in the human genome. Nat Genet 51:88–95. https://doi.org/10.1038/s41588-018-0294-6
doi: 10.1038/s41588-018-0294-6 pubmed: 30531870
Heilstedt HA, Burgess DL, Anderson AE et al (2002) Loss of the potassium channel β-subunit gene, KCNAB2, is associated with epilepsy in patients with 1p36 deletion syndrome. Epilepsia 42:1103–1111. https://doi.org/10.1046/j.1528-1157.2001.08801.x
doi: 10.1046/j.1528-1157.2001.08801.x
Karczewski KJ, Francioli LC, Tiao G et al (2020) The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581:434–443. https://doi.org/10.1038/s41586-020-2308-7
doi: 10.1038/s41586-020-2308-7 pubmed: 32461654 pmcid: 7334197
Marfella CGA, Imbalzano AN (2007) The Chd family of chromatin remodelers. Mutat Res Fundam Mol Mech Mutagen 618:30–40. https://doi.org/10.1016/j.mrfmmm.2006.07.012
doi: 10.1016/j.mrfmmm.2006.07.012
Merner N, Forgeot d’Arc B, Bell SC et al (2016) A de novo frameshift mutation in chromodomain helicase DNA-binding domain 8 (CHD8): a case report and literature review. Am J Med Genet 170:1225–1235. https://doi.org/10.1002/ajmg.a.37566
doi: 10.1002/ajmg.a.37566
Ng PC (2003) SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 31:3812–3814. https://doi.org/10.1093/nar/gkg509
doi: 10.1093/nar/gkg509 pubmed: 12824425 pmcid: 168916
Nitarska J, Smith JG, Sherlock WT et al (2016) A Functional switch of NuRD chromatin remodeling complex subunits regulates mouse cortical development. Cell Rep 17:1683–1698. https://doi.org/10.1016/j.celrep.2016.10.022
doi: 10.1016/j.celrep.2016.10.022 pubmed: 27806305 pmcid: 5149529
O’Roak BJ, Deriziotis P, Lee C et al (2011) Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. Nat Genet 43:585–589. https://doi.org/10.1038/ng.835
doi: 10.1038/ng.835 pubmed: 21572417 pmcid: 3115696
Pierson TM, Otero MG, Grand K et al (2019) The NuRD complex and macrocephaly associated neurodevelopmental disorders. Am J Med Genet 181:548–556. https://doi.org/10.1002/ajmg.c.31752
doi: 10.1002/ajmg.c.31752 pubmed: 31737996
Pilarowski GO, Vernon HJ, Applegate CD et al (2018) Missense variants in the chromatin remodeler CHD1 are associated with neurodevelopmental disability. J Med Genet 55:561–566. https://doi.org/10.1136/jmedgenet-2017-104759
doi: 10.1136/jmedgenet-2017-104759 pubmed: 28866611
Radio FC, Pang K, Ciolfi A et al (2021) SPEN haploinsufficiency causes a neurodevelopmental disorder overlapping proximal 1p36 deletion syndrome with an episignature of X chromosomes in females. Am J Hum Genet 108(3):502–516. https://doi.org/10.1016/j.ajhg.2021.01.015
doi: 10.1016/j.ajhg.2021.01.015 pubmed: 33596411
Rentzsch P, Witten D, Cooper GM et al (2019) CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res 47:D886–D894. https://doi.org/10.1093/nar/gky1016
doi: 10.1093/nar/gky1016 pubmed: 30371827
Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the association for molecular pathology. Genet Med 17:405–423. https://doi.org/10.1038/gim.2015.30
doi: 10.1038/gim.2015.30 pubmed: 25741868 pmcid: 4544753
Romero OA, Sanchez-Cespedes M (2014) The SWI/SNF genetic blockade: effects in cell differentiation, cancer and developmental diseases. Oncogene 33:2681–2689. https://doi.org/10.1038/onc.2013.227
doi: 10.1038/onc.2013.227 pubmed: 23752187
Samocha KE, Kosmicki JA, Karczewski KJ et al (2017) Regional missense constraint improves variant deleteriousness prediction. BioRxiv. https://doi.org/10.1101/148353
doi: 10.1101/148353
Schwarz JM, Cooper DN, Schuelke M, Seelow D (2014) MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods 11:361–362. https://doi.org/10.1038/nmeth.2890
doi: 10.1038/nmeth.2890 pubmed: 24681721
Shimada S, Shimojima K, Okamoto N et al (2015) Microarray analysis of 50 patients reveals the critical chromosomal regions responsible for 1p36 deletion syndrome-related complications. Brain Dev 37:515–526. https://doi.org/10.1016/j.braindev.2014.08.002
doi: 10.1016/j.braindev.2014.08.002 pubmed: 25172301
Siakallis L, Tan AP, Chorbachi R, Mankad K (2019) A unique case of CHARGE syndrome with craniosynostosis. Childs Nerv Syst 35:11–13. https://doi.org/10.1007/s00381-018-4005-5
doi: 10.1007/s00381-018-4005-5 pubmed: 30498854
Siepel A (2005) Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res 15:1034–1050. https://doi.org/10.1101/gr.3715005
doi: 10.1101/gr.3715005 pubmed: 16024819 pmcid: 1182216
Snijders Blok L, Rousseau J, Twist J et al (2018) CHD3 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and impaired speech and language. Nat Commun 9:4619. https://doi.org/10.1038/s41467-018-06014-6
doi: 10.1038/s41467-018-06014-6 pubmed: 30397230 pmcid: 6218476
Sobreira N, Schiettecatte F, Valle D, Hamosh A (2015) GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. Hum Mutat 36:928–930. https://doi.org/10.1002/humu.22844
doi: 10.1002/humu.22844 pubmed: 26220891 pmcid: 4833888
Suls A, Jaehn JA, Kecskés A et al (2013) De novo loss-of-function mutations in CHD2 cause a fever-sensitive myoclonic epileptic encephalopathy sharing features with Dravet syndrome. Am J Hum Genet 93:967–975. https://doi.org/10.1016/j.ajhg.2013.09.017
doi: 10.1016/j.ajhg.2013.09.017 pubmed: 24207121 pmcid: 3824114
Tønne E, Due-Tønnessen BJ, Mero I-L et al (2020) Benefits of clinical criteria and high-throughput sequencing for diagnosing children with syndromic craniosynostosis. Eur J Hum Genet. https://doi.org/10.1038/s41431-020-00788-4
doi: 10.1038/s41431-020-00788-4 pubmed: 33288889
Tyagi M, Imam N, Verma K, Patel AK (2016) Chromatin remodelers: we are the drivers!! Nucleus 7:388–404. https://doi.org/10.1080/19491034.2016.1211217
doi: 10.1080/19491034.2016.1211217 pubmed: 27429206 pmcid: 5039004
Vissers LELM, van Ravenswaaij CMA, Admiraal R et al (2004) Mutations in a new member of the chromodomain gene family cause CHARGE syndrome. Nat Genet 36:955–957. https://doi.org/10.1038/ng1407
doi: 10.1038/ng1407 pubmed: 15300250
Weiss K, Terhal PA, Cohen L et al (2016) De novo mutations in CHD4, an ATP-dependent chromatin remodeler gene, cause an intellectual disability syndrome with distinctive dysmorphisms. Am J Hum Genet 99:934–941. https://doi.org/10.1016/j.ajhg.2016.08.001
doi: 10.1016/j.ajhg.2016.08.001 pubmed: 27616479 pmcid: 5065651
Weiss K, Lazar HP, Kurolap A et al (2020) The CHD4-related syndrome: a comprehensive investigation of theclinical spectrum, genotype–phenotype correlations, and molecular basis. Genet Med 22:389–397. https://doi.org/10.1038/s41436-019-0612-0
doi: 10.1038/s41436-019-0612-0 pubmed: 31388190
Woodage T, Basrai MA, Baxevanis AD et al (1997) Characterization of the CHD family of proteins. Proc Natl Acad Sci 94:11472–11477. https://doi.org/10.1073/pnas.94.21.11472
doi: 10.1073/pnas.94.21.11472 pubmed: 9326634
Zentner GE, Layman WS, Martin DM, Scacheri PC (2010) Molecular and phenotypic aspects of CHD7 mutation in CHARGE syndrome. Am J Med Genet 152A:674–686. https://doi.org/10.1002/ajmg.a.33323
doi: 10.1002/ajmg.a.33323 pubmed: 20186815
Zhuang T, Hess RA, Kolla V et al (2014) CHD5 is required for spermiogenesis and chromatin condensation. Mech Dev 131:35–46. https://doi.org/10.1016/j.mod.2013.10.005
doi: 10.1016/j.mod.2013.10.005 pubmed: 24252660

Auteurs

Ilaria Parenti (I)

Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Daphné Lehalle (D)

Département de Génétique, Centre de Référence Déficiences Intellectuelles de Causes Rares, Groupe Hospitalier Pitié-Salpêtrière and Hôpital Trousseau, APHP, Sorbonne Université, Paris, France.

Caroline Nava (C)

Institut du Cerveau (ICM), UMR S 1127, Inserm U1127, CNRS UMR 7225, Sorbonne Université, 75013, Paris, France.

Erin Torti (E)

GeneDx, Gaithersburg, MD, USA.

Elsa Leitão (E)

Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Richard Person (R)

GeneDx, Gaithersburg, MD, USA.

Takeshi Mizuguchi (T)

Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, 236-0004, Japan.

Naomichi Matsumoto (N)

Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, 236-0004, Japan.

Mitsuhiro Kato (M)

Department of Pediatrics, Showa University School of Medicine, Tokyo, 142-8666, Japan.

Kazuyuki Nakamura (K)

Department of Pediatrics, Yamagata University Faculty of Medicine, Yamagata, 990-9585, Japan.

Stella A de Man (SA)

Department of Pediatrics, Amphia Hospital, Breda, The Netherlands.

Heidi Cope (H)

Division of Medical Genetics, Department of Pediatrics, Duke University School of Medicine, Durham, NC 27710, USA.

Vandana Shashi (V)

Division of Medical Genetics, Department of Pediatrics, Duke University School of Medicine, Durham, NC 27710, USA.

Jennifer Friedman (J)

Departments of Neuroscience and Pediatrics, Division of Neurology, Rady Children's Hospital, UCSD, San Diego and Rady Children's Institute for Genomic Medicine, San Diego, CA, USA.

Pascal Joset (P)

Institute of Medical Genetics, University of Zurich, Schlieren, 8952, Zurich, Switzerland.
Rare Disease Initiative Zurich, Clinical Research Priority Program for Rare Diseases University of Zurich, 8032, Zurich, Switzerland.

Katharina Steindl (K)

Institute of Medical Genetics, University of Zurich, Schlieren, 8952, Zurich, Switzerland.
Rare Disease Initiative Zurich, Clinical Research Priority Program for Rare Diseases University of Zurich, 8032, Zurich, Switzerland.

Anita Rauch (A)

Institute of Medical Genetics, University of Zurich, Schlieren, 8952, Zurich, Switzerland.
Rare Disease Initiative Zurich, Clinical Research Priority Program for Rare Diseases University of Zurich, 8032, Zurich, Switzerland.

Irena Muffels (I)

Department of Metabolic Diseases, University Medical Centre Utrecht, Utrecht, The Netherlands.

Peter M van Hasselt (PM)

Department of Metabolic Diseases, University Medical Centre Utrecht, Utrecht, The Netherlands.

Florence Petit (F)

Clinique de Génétique, CHU Lille, 59000, Lille, France.

Thomas Smol (T)

Institut de Génétique Médicale, CHRU Lille, Université de Lille, Lille, France.

Gwenaël Le Guyader (G)

Service de Génétique Médicale, CHU de Poitiers, Poitiers, France.
EA3808 NEUVACOD, University of Poitiers, Poitiers, France.

Frédéric Bilan (F)

Service de Génétique Médicale, CHU de Poitiers, Poitiers, France.
EA3808 NEUVACOD, University of Poitiers, Poitiers, France.

Arthur Sorlin (A)

Unité Fonctionnelle d'Innovation Diagnostique des Maladies Rares, FHU-TRANSLAD, France Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (TRANSLAD), Centre Hospitalier Universitaire Dijon Bourgogne, CHU Dijon Bourgogne, Dijon, France.
INSERM-Université de Bourgogne UMR1231 GAD « Génétique Des Anomalies du Développement », FHU-TRANSLAD, UFR Des Sciences de Santé, Dijon, France.
Centre de Référence Maladies Rares «Anomalies du Développement et Syndromes Malformatifs », Centre de Génétique, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.

Antonio Vitobello (A)

Unité Fonctionnelle d'Innovation Diagnostique des Maladies Rares, FHU-TRANSLAD, France Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (TRANSLAD), Centre Hospitalier Universitaire Dijon Bourgogne, CHU Dijon Bourgogne, Dijon, France.
INSERM-Université de Bourgogne UMR1231 GAD « Génétique Des Anomalies du Développement », FHU-TRANSLAD, UFR Des Sciences de Santé, Dijon, France.

Christophe Philippe (C)

Unité Fonctionnelle d'Innovation Diagnostique des Maladies Rares, FHU-TRANSLAD, France Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (TRANSLAD), Centre Hospitalier Universitaire Dijon Bourgogne, CHU Dijon Bourgogne, Dijon, France.
INSERM-Université de Bourgogne UMR1231 GAD « Génétique Des Anomalies du Développement », FHU-TRANSLAD, UFR Des Sciences de Santé, Dijon, France.

Ingrid M B H van de Laar (IMBH)

Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Marjon A van Slegtenhorst (MA)

Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Philippe M Campeau (PM)

CHU Sainte-Justine Research Center, Montreal, QC, H3T 1C5, Canada.
Sainte-Justine Hospital, University of Montreal, Montreal, QC, H3T 1C5, Canada.

Ping Yee Billie Au (PYB)

Department of Medical Genetics and Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, T2N 4N1, Canada.

Mitsuko Nakashima (M)

Department of Biochemistry, Hamamatsu University School of Medicine, Hamamatsu, 431-3192, Japan.

Hirotomo Saitsu (H)

Department of Biochemistry, Hamamatsu University School of Medicine, Hamamatsu, 431-3192, Japan.

Tatsuya Yamamoto (T)

Department of Pediatrics, Hirosaki University Graduate School of Medicine and School of Medicine, Hirosaki, 036-8562, Japan.

Yumiko Nomura (Y)

Department of Pediatrics, Hirosaki National Hospital, Hirosaki, 036-8545, Japan.
Aomori City Health Center, Aomori, 030-0962, Japan.

Raymond J Louie (RJ)

Greenwood Genetic Center, Greenwood, SC, 29646, USA.

Michael J Lyons (MJ)

Greenwood Genetic Center, Greenwood, SC, 29646, USA.

Amy Dobson (A)

Greenwood Genetic Center, Greenwood, SC, 29646, USA.

Astrid S Plomp (AS)

Department of Clinical Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

M Mahdi Motazacker (MM)

Laboratory of Genome Diagnostics, Department of Clinical Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Frank J Kaiser (FJ)

Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Andrew T Timberlake (AT)

Hansjörg Wyss Department of Plastic Surgery, NYU Langone Health, New York, NY, USA.

Sabine A Fuchs (SA)

Department of Metabolic Diseases, University Medical Centre Utrecht, Utrecht, The Netherlands.

Christel Depienne (C)

Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, Essen, Germany. christel.depienne@uni-due.de.
Institut du Cerveau (ICM), UMR S 1127, Inserm U1127, CNRS UMR 7225, Sorbonne Université, 75013, Paris, France. christel.depienne@uni-due.de.

Cyril Mignot (C)

Département de Génétique, Centre de Référence Déficiences Intellectuelles de Causes Rares, Groupe Hospitalier Pitié-Salpêtrière and Hôpital Trousseau, APHP, Sorbonne Université, Paris, France. cyril.mignot@aphp.fr.
Institut du Cerveau (ICM), UMR S 1127, Inserm U1127, CNRS UMR 7225, Sorbonne Université, 75013, Paris, France. cyril.mignot@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH